alendronate has been researched along with Lung Neoplasms in 10 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 8.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 4.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| " Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia." | 4.79 | [Paraneoplastic syndrome]. ( Hara, N; Nakanishi, Y; Takayama, K, 1997) |
| " In this study we used a standardized ATP-based tumor chemosensitivity assay (ATP-TCA) to measure the activity of alendronate, clodronate and zoledronic acid in five ovarian carcinoma cell lines and human solid tumors (breast, lung, ovarian, unknown primary carcinoma, and cutaneous and uveal melanoma) (n=34)." | 3.73 | Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. ( Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M, 2005) |
| "Malignant melanoma has previously been reported with paraneoplastic syndromes including dermatomyositis." | 1.37 | Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon. ( Tu, J; Von Nida, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhakamy, NA | 1 |
| Okbazghi, SZ | 1 |
| A Alfaleh, M | 1 |
| H Abdulaal, W | 1 |
| Bakhaidar, RB | 1 |
| Alselami, MO | 1 |
| Zahrani, MA | 1 |
| Alqarni, HM | 1 |
| F Alghaith, A | 1 |
| Alshehri, S | 1 |
| Badr-Eldin, SM | 1 |
| Aldawsari, HM | 1 |
| Al-Hejaili, OD | 1 |
| Aldhabi, BM | 1 |
| Mahdi, WA | 1 |
| Bai, SB | 1 |
| Cheng, Y | 1 |
| Liu, DZ | 1 |
| Ji, QF | 1 |
| Liu, M | 1 |
| Zhang, BL | 1 |
| Mei, QB | 1 |
| Zhou, SY | 1 |
| Li, M | 1 |
| Zhong, M | 1 |
| Guan, C | 1 |
| Chen, LX | 1 |
| Ning, GZ | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Zhang, D | 1 |
| Wu, QL | 1 |
| Zhang, TS | 1 |
| Cheng, L | 1 |
| Feng, SQ | 1 |
| Tu, J | 1 |
| Von Nida, J | 1 |
| Martins, MA | 1 |
| Martins, MD | 1 |
| Lascala, CA | 1 |
| Curi, MM | 1 |
| Migliorati, CA | 1 |
| Tenis, CA | 1 |
| Marques, MM | 1 |
| Onuma, E | 1 |
| Azuma, Y | 1 |
| Saito, H | 1 |
| Tsunenari, T | 1 |
| Watanabe, T | 1 |
| Hirabayashi, M | 1 |
| Sato, K | 1 |
| Yamada-Okabe, H | 1 |
| Ogata, E | 1 |
| Knight, LA | 1 |
| Conroy, M | 1 |
| Fernando, A | 1 |
| Polak, M | 1 |
| Kurbacher, CM | 1 |
| Cree, IA | 1 |
| Diskin, CJ | 1 |
| Stokes, TJ | 1 |
| Dansby, LM | 1 |
| Radcliff, L | 1 |
| Carter, TB | 1 |
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Hara, N | 1 |
2 reviews available for alendronate and Lung Neoplasms
| Article | Year |
|---|---|
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Colorectal Neoplasms; Female; Humans; | 2015 |
[Paraneoplastic syndrome].
Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated | 1997 |
8 other studies available for alendronate and Lung Neoplasms
| Article | Year |
|---|---|
Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.
Topics: A549 Cells; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cell Cycle; Drug | 2022 |
Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Lung | 2020 |
Bisphosphonates and risk of lung cancer: Protocol for a systematic review and meta-analysis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Protocols; Diphosphonates; Humans; Lung Neop | 2021 |
Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon.
Topics: Adult; Alendronate; Antibodies, Antinuclear; Calcium; Dermatologic Agents; Dermatomyositis; Drug The | 2011 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2012 |
Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Bone Resorption; Calcitonin; Calcium; Cell Line, Tumor | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemoth | 2005 |
Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin.
Topics: Aged; Alendronate; Calcitonin; Diphosphonates; Female; Humans; Hypercalcemia; Lung Neoplasms | 2007 |